维普中文期刊产品整合服务
13篇 您的检索式:作者名="ASTERIOS G"
    题名 作者 年代 出处 被引量
1Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome显示文摘AIM: To investigate the effect of rosuvastatin monotherapy on non-alcoholic steatohepatitis(NASH). At present there is no effective treatment for non-alcoholic fatty liver disease or its advanced form NASH.METHODS: This prospective study included 20 biopsy proven patients with NASH, metabolic syndrome(Met S) and dyslipidaemia. Biochemical parameters of the blood of the patients and an ultrasonography of the liver were performed at baseline. Then patients receivedlifestyle advice and were treated for a 12 mo period with rosuvastatin(10 mg/d) monotherapy. Patients were re-evaluated during the study at 3 mo intervals, during which biochemical parameters of the blood were measured including liver enzymes. A repeat biopsy and ultrasonography of the liver were performed at the end of the study in all 20 patients. Changes in liver enzymes, fasting plasma glucose, serum creatinine, serum uric acid(SUA), high sensitivity C reactive protein(hs CRP) and lipid profile were assessed every 3 mo. The primary endpoint was the resolution of NASH and the secondary endpoints were the changes in liver enzyme and lipid values.RESULTS: The repeat liver biopsy and ultrasonography showed complete resolution of NASH in 19 patients, while the 20 th, which had no improvement but no deterioration either, developed arterial hypertension and substantial rise in triglyceride levels during the study, probably due to changes in lifestyle including alcohol abuse. Serum alanine transaminase, aspartate transaminase, and γ-glutamyl transpeptidase were normalised by the 3rd treatment month(ANOVA P < 0.001), while alkaline phosphatase activities by the 6th treatment month(ANOVA, P = 0.01). Fasting plasma glucose and glycated haemoglobin were significantly reduced(P < 0.001). Lipid values were normalised by the 3rd treatment month. No patient had Met S by the 9th treatment month. Body mass index and waist circumference remained unchanged during the study. Thus, changes in liver pathology and function should be attributed solely to rosuvastatin treatment. A limitation of the study is the absence of a control group.CONCLUSION: These findings suggest that rosuvastatin monotherapy could ameliorate biopsy proven NASH and resolve Met S within 12 mo. These effects and the reduction of fasting plasma glucose and SUA levels may reduce the risk of vascular and liver morbidity and mortality in NASH patients. These findings need confirmation in larger studies.Konstantinos Kargiotis Vasilios G Athyros Olga Giouleme Niki Katsiki Evangelia Katsiki Panagiotis Anagnostis Chrysoula Boutari Michael Doumas Asterios Karagiannis Dimitri P Mikhailidis 2015World Journal of Gastroenterology2015,21,25:18
2The role of ankle brachial index and carotid intima-media thickness in vascular risk stratification显示文摘Konstantinos Tziomalos Vasilios G Athyros Asterios Karagiannis Dimitri P Mikhailidis 2010Current Opinion in Cardiology2010,,4:2
3Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis显示文摘Vasilios G Athyros Konstantinos Tziomalos Thomas D Gossios Theodora Griva Panagiotis Anagnostis Konstantinos Kargiotis Efstathios D Pagourelias Eleni Theocharidou Asterios Karagiannis Dimitri P Mikhailidis 2010The Lancet2010,,9756:2
4Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease:an update显示文摘Vasilios G Athyros Konstantinos Tziomalos Niki Katsiki Michael Doumas Asterios Karagiannis Dimitri P Mikhailidis 2015World Journal of Gastroenterology2015,,22:2
5Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis显示文摘Vasilios G Athyros Konstantinos Tziomalos Thomas D Gossios Theodora Griva Panagiotis Anagnostis Konstantinos Kargiotis Efstathios D Pagourelias Eleni Theocharidou Asterios Karagiannis Dimitri P Mikhailidis 2010The Lancet2010,,9756:1
6Influence of loading on metal surface area for Ag/α-Al2O3 catalysts显示文摘ASTERIOS G BILAL S ARVIND V 1993Journal of Catalysis1993,139,1:1
7Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis显示文摘Vasilios G Athyros Konstantinos Tziomalos Thomas D Gossios Theodora Griva Panagiotis Anagnostis Konstantinos Kargiotis Efstathios D Pagourelias Eleni Theocharidou Asterios Karagiannis Dimitri P Mikhailidis 20102010 (9756)2010,,9756:1
8Reviewed work(s): The democratic corporation: a radical prescription for recreating corporate America and rediscovering success 显示文摘ASTERIOS G KEFALAS S 1996The Academy of Management Review1996,21,2:1
9Macronutrients requirements of the dino? agellate protoeeratium reticulatum显示文摘Juan J G R Asterio S M Maradel C C G 2009Harmful Algae2009,8,2:1
10Growth and biochemical characterization of microalgal biomas produced in bubble column and airlift photobioreactor: :studies in fed-batch culture显示文摘Asterio S M Marie Carmen C G Francisco G C 2002Enzyme and Microbial Technology2002,31,:1
11The role of capsule endoscopy in the evaluation and treatment of obscure-overt gastrointestinal bleeding during daily clinical practice:a prospective multicenter study显示文摘Panagiotis K Georgia L Asterios G 2014Scand J Gastroenterol2014,49,7:1
12Atorvastatin: safety and tolerability显示文摘Vasilios G Athyros Konstantinos Tziomalos Asterios Karagiannis Dimitri P Mikhailidis 2010Expert Opinion on Drug Safety2010,,4:1
13Design and characterisation of the staggered herringbone mixer显示文摘SUET P K ASTERIOS G 2008Chemical Engineering Journal2008,142,:1
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费